Crennen Lyndsey Elizabeth Sells Mesa Laboratories Shares

On June 22, 2026, Crennen Lyndsey Elizabeth, Chief Accounting Officer at Mesa Laboratories, Inc. (NasdaqGS: MLAB), sold 442 shares of the company's stock. The shares were sold at an average price of $89.5 each, totaling $39,559. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Mesa Laboratories, Inc.

Besides Crennen Lyndsey Elizabeth's transaction, other key insiders at Mesa Laboratories also made trades around the same time. On June 22, 2026, Brian David Archbold, Senior Vice President of Operations, sold 2,516 shares at the same price of $89.5. John Sakys, the Chief Financial Officer, sold 2,827 shares at $89.5 on the same day. Earlier, on June 18, 2026, Sakys purchased 2,282 shares at $95.1, and Archbold bought 1,859 shares at the same price.

Other Institutional Activity in Mesa Laboratories

Several institutional investors have made changes to their stakes in Mesa Laboratories. Long Path Partners LP increased its holdings by 178,360 shares, bringing its total to 405,583 shares valued at approximately $35.9 million, marking a 78.5% increase. Meanwhile, BlackRock, Inc. trimmed its position by 4,815 shares, maintaining 393,851 shares worth about $34.8 million, a slight 1.2% decrease. Boston Partners added 55,335 shares to its stake, now holding 268,711 shares valued at $23.8 million, reflecting a 25.9% increase. Select Equity Group, L.P. grew its holdings by 29,450 shares to 235,885 shares, valued at $20.9 million, a 14.3% increase. Vanguard Capital Management LLC opened a new position with 232,643 shares worth $20.6 million.

Mesa Laboratories, Inc. Stock Down 28.7%

Shares of Mesa Laboratories, Inc. traded near $93.23 on Tuesday. The company boasts a market cap of approximately $515.1 million and has a P/E ratio of 77.05, with a forward P/E of 7.60. The stock's beta is 0.927, indicating lower volatility relative to the market. Over the past 52 weeks, the stock has ranged from a low of $55.45 to a high of $113.99. It has a 50-day moving average of $101.99 and a 200-day moving average of $84.97. Mesa Laboratories maintains a current ratio of 1.717 and a quick ratio of 1.174, with a debt-to-equity ratio of 90.65.

Recent Earnings

Mesa Laboratories reported revenue of $249.1 million, with a modest growth rate of 2.6%. The company achieved an earnings per share (EPS) of $1.21. Its net margin stands at 2.7%, and return on equity (ROE) is 3.9%. The next earnings release is scheduled for August 5, 2026.

Dividend

Mesa Laboratories offers an annual dividend rate of $0.64, yielding 0.67%. The company's dividend payout ratio is 52.89%.

Analysts Set New Price Targets

Wells Fargo maintained its hold rating on Mesa Laboratories, setting a price target of $94 on February 4, 2026. The consensus among analysts is a hold, with a mean target price of $112 based on two opinions.

About Mesa Laboratories

Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, develops and manufactures life sciences tools and quality control products. It operates in sectors like sterilization and disinfection control, clinical genomics, biopharmaceutical development, and calibration solutions. The company serves various industries, including pharmaceutical, medical device, and healthcare sectors across North America, Europe, and Asia Pacific. Led by CEO Dr. Siddhartha Chandrakant Kadia, the company employs around 717 people.

Bottom Line

Crennen Lyndsey Elizabeth's recent sale of Mesa Laboratories shares is part of ongoing insider activity at the company. Investors often track such moves for insights into management's confidence levels. However, it's important to remember that these transactions can be for personal reasons and aren't necessarily reflective of the company's future prospects.